GlassScriptPhysician profile
Anthony Cavazos
NPI 1104944263
$5,088.19
in general payments reported to CMS, 2019-2025
24 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Geriatric Medicine (Family Medicine) provider received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,317 · 2020: $407 · 2021: $759 · 2022: $830 · 2023: $926 · 2024: $563 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,736 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,939.04 | 2019-2023 | Xeomin |
| Novo Nordisk INC | $787.87 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $592.98 | 2020-2025 | Mounjaro, Zepbound |
| Antares Pharma, INC. | $512.72 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $219.27 | 2022-2024 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $215.35 | 2019-2025 | Breztri, Farxiga |
| Allergan, INC. | $148.32 | 2019-2022 | |
| Amgen INC. | $105.05 | 2019-2024 | Repatha |
| Amarin Pharma, INC. | $94.76 | 2020-2021 | |
| Halozyme INC | $88.19 | 2023 | |
| Tolmar, INC. | $58.28 | 2023-2024 | |
| Azurity Pharmaceuticals, INC. | $51.30 | 2023-2025 | Azmiro, Adthyza |
| Acerus Pharmaceuticals Corporation | $45.15 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.38 | 2021-2022 | |
| Acella Pharmaceuticals, LLC | $37.31 | 2024 | NP Thyroid 60 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $34.85 | 2024 | Tlando |
| Currax Pharmaceuticals LLC | $16.51 | 2024 | Contrave |
| Depuy Synthes Sales INC. | $16.41 | 2019 | |
| Echosens North America, INC. | $14.76 | 2025 | Fibroscan |
| Jazz Pharmaceuticals INC. | $14.34 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.98 | 2019 | |
| Eisai INC. | $13.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Cavazos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.